Navigation Links
Alteon Initiates Phase 2 Trial of ALT-2074 in Diabetes and Haptoglobin 2-2

Alteon Inc. announced today that it has dosed its first patient in a 60-patient Phase 2 clinical trial (Study 201) of ALT-2074, its lead glutathione peroxidase mimetic, in diabetic patients with a variant of haptoglobin that renders them at high risk for cardiovascular complications.

This dose escalating study is designed to evaluate ALT-2074's ability to lower inflammatory cardiovascular biomarkers in patients with an elevated risk for cardiovascular events.

It builds on positive data from previous cardiovascular animal studies. ALT- 2074's activity in prior clinical trials demonstrated its safety and ability to lower inflammatory markers in ulcerative colitis.

'The initiation of Study 201 is a key milestone in our program for the development of ALT-2074 as a treatment for diabetic patients with a high risk of cardiovascular events,'said Malcolm W. MacNab, M.D., Ph.D., Alteon's Vice President, Clinical Development.

'We are enthusiastic about the potential that ALT-2074 has demonstrated in our preclinical models and we are aggressively pursuing clinical development in this indication.'

Diabetes and Metabolic Syndrome, diseases linked to obesity and increased oxidative stress, are growing in epidemic proportions in the United States and many other developed countries.

The major complications associated with these diseases are cardiovascular in nature, and lead to such events as stroke, heart attack, kidney failure and death. Not all patients with diabetes, however, experience these complications.

Several multinational studies have demonstrated that the increased risk of cardiovascular disease attributed to diabetes is more aptly attributed to the development of diabetes 'on top of' a predisposing genetic factor called Haptoglobin 2-2 (Hp2-2), which is found in 40% of the human population.

The combination of diabetes and Hp2-2 increases the susceptibil
'"/>




Page: 1 2

Related medicine news :

1. Bird Flu: Orissa Initiates Protective Measures
2. Biota Initiates Drug Testing War against Common Cold
3. Russia Initiates Mass Vaccination Of Poultry To Restrict Bird Flu
4. Government Initiates A Program To Curb HIV
5. Peregrine Pharmaceuticals Initiates Patient Enrollment In New Cotara(R) Brain Cancer Trial
6. SARS-Free Taiwan to Mark End Phase of Global Fight
7. Spray on contraceptive clears Phase I trial
8. Phase 3 trials of two multi-kinase inhibitors against cancer
9. Antigenics Pharmaceuticals plans for Phase III trial of its Melanoma vaccine
10. Phase II trails of new HIV vaccine to be held in South Africa
11. FDA approves Phase 0 trial which tests experimental drugs on humans
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Alteon Initiates Phase Trial ALT Diabetes and Haptoglobin

(Date:12/24/2014)... Today, UWDress.com, the famous women’s dress supplier, has presented its ... site-wide wedding gown promotion. , For those who ... unexpected way, the collection should be a great choice. The ... and they are available with custom service. , Now, all ... up to 75% off; most of them come in hot ...
(Date:12/24/2014)... 2014 Mike Billings , PT, ... Derek Fenwick, PT, MBA, GCS, Director of Professional ... from the passing of the Improving Medicare Post-Acute ... this taping of the Infinicast, the two leaders discuss ... Social Security Act to standardize post-acute assessment data for ...
(Date:12/24/2014)... -- The holidays can be a challenge for people who ... and drinks. "This is the season in which many ... Dr. David Dodick, chair of the American Migraine Foundation, said ... to think through food and beverage choices, to help reduce ... professor of neurology at the Mayo Clinic in Scottsdale, Ariz. ...
(Date:12/24/2014)... Dec. 24, 2014 (HealthDay News) -- Adults who ... risk of migraine headaches, suggests a study published ... . "Childhood maltreatment can have long-lasting effects, ... in adulthood," study author Dawn Buse, director of ... York City, said in a journal news release. ...
(Date:12/24/2014)... WEDNESDAY, Dec. 24, 2014 (HealthDay News) -- A lab ... Prevention may have been exposed to the Ebola virus ... And up to a dozen other lab workers ... late Wednesday afternoon. The possible exposure occurred Monday ... a sample of the potentially lethal virus to another ...
Breaking Medicine News(10 mins):Health News:Buy Cheap Long Sleeve Wedding Gowns At UWDress.com 2Health News:Latest Episode of Infinicast Features Infinity Rehab President Discussing IMPACT Act of 2014 and Changes for Post-Acute Therapy Providers in 2015 2Health News:Expert Offers Tips for Preventing Holiday Migraines 2Health News:Abuse in Childhood Tied to Migraines in Adulthood 2Health News:CDC Monitors Lab Worker for Possible Ebola Exposure 2
... for Helicobacter pylori as the decay-accelerating factor (DAF), a ... , Blocking this interaction could lead to new drugs ... gastric cancer. The research appears as the ‘Paper of ... Journal of Biological Chemistry, an American Society for Biochemistry ...
... In a new clinical development partnership being launched ... arm, Cancer Research Technology (CRT) plans to take ... for not showing enough commercial promise following their ... new treatments from anti-cancer drugs that have been ...
... by the defence attorneys of the AIIMS hospital, has sought ... where a boy, suffering from cancer, got inflicted with AIDS ... ,The victim, who was nine years old at the ... for treatment of cancer, supposedly has contracted HIV due to ...
... drug Zoloft (sertraline) may avoid in preventing recurring of ... interval between the depressive episodes. ,One in every ... the study, reports foodconsumer.org. ,Researchers studied 152 ... recovered from depression during treatment with Zoloft -- 79 ...
... recent conducted at University of Michigan Health Systems in ... greater expectations of doom from their screening //mammography for ... not these expectations were unusually high or unrealistic. ... an outpatient clinic for screening mammography. The participants were ...
... Computer keyboards used in hospitals are a reservoir for ... to be disinfected every day, a new study warns.// ... various locations inside University of North Carolina hospitals and ... two types of bacteria, reports the science portal HealthCentral. ...
Cached Medicine News:Health News:Receptor for H.pylori Identified in Stomach 2Health News:Cancer Research UK Offers New Hope To Cancer Patients 2Health News:A Boy Undergoing Treatment For Cancer Gets AIDS At AIIMS 2Health News:Most Women Have Unrealistic Expectations From Screening Mammography 2Health News:Computer Keyboards In Hospitals Could Spread Infection To Patients 2
(Date:12/24/2014)... , Dec. 24, 2014  Actavis plc ... the Company has received a complete response letter ... for its New Drug Application (NDA) for the ... the treatment of hypertension.   Photo - ... are disappointed in the receipt of a complete ...
(Date:12/24/2014)... Trade Commission (ITC) issued its final decision in the case ... issued on December 23, the ITC ruled in favor of ... invalid. BMC President, James Xu called ... the ITC,s decision in this case. This victory for us ... beginning on the key patents in the case. ResMed chose ...
(Date:12/24/2014)... -- PuraMed BioScience®, Inc., (OTC Pink: PMBS), a researcher, ... products, announced it received the initial funding to begin ... relief product, for planned distribution to 1,000 medical and ... Washington State , and ... Advanced headache relief gel formulation completed, PuraMed BioScience has ...
Breaking Medicine Technology:Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 2Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 3Actavis Confirms Complete Response Letter for Nebivolol/Valsartan Fixed-Dose Combination for Hypertension 4ITC Final Decision Goes Against ResMed (RMD) Monumental Win for 3B/BMC 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 2PuraMed BioScience Nears Final Stages Needed for Distribution of MigraPure H 3
... Innovations, LLC, a leading developer and marketer of high ... of their new European office in Enschede, the Netherlands ... management team and new European staff, local Enschede dignitaries ... of Economic Affairs in The Netherlands and Mr. Jan ...
... 31, 2011 Omni Bio Pharmaceutical, Inc. (OTC BB: OMBP), ... To the Shareholders of Omni Bio Pharmaceutical, Inc.: ... first month as the Chief Executive Officer of Omni Bio ... a close, this is an appropriate juncture to update our ...
Cached Medicine Technology:Freedom Innovations Opens New European Headquarters 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 2Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 3Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 4Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 5Omni Bio Pharmaceutical, Inc's. CEO Issues Letter to Shareholders 6
... been selling replacement bulbs on ... we are extremely proud of ... out our catalog of replacement ... light bulbs specials. ,Check ...
... Bulb Direct has been selling ... since 1996, and we are ... satisfaction guarantee. Check out our ... see our discount light bulbs ...
... Symphony family of Pacemakers, Ela presents the ... lighter than a passport, will take your ... technologies, and delivering powerful monitoring. ELA ... dual-chamber and atrial tracking modes in patients ...
With the Symphony family of Pacemakers, Ela presents the most advanced technology on the market. Symphony, lighter than a passport, will take your patients further, offering fast follow-up, using new...
Medicine Products: